Merck & Co., Inc. Increase (Decrease) in Accounts Payable, Trade
Merck & Co., Inc. (MRK) reported Increase (Decrease) in Accounts Payable, Trade of $110.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-02-24
- Merck & Co., Inc. increase (decrease) in accounts payable, trade for the quarter ending 2009-12-31 was -$73.00M.
- Merck & Co., Inc. increase (decrease) in accounts payable, trade for the quarter ending 2009-09-30 was -$61.00M, a 264.86% decline year-over-year.
- Merck & Co., Inc. increase (decrease) in accounts payable, trade for the quarter ending 2008-12-31 was -$16.00M.
- Merck & Co., Inc. increase (decrease) in accounts payable, trade for the quarter ending 2008-09-30 was $37.00M.
- Merck & Co., Inc. increase (decrease) in accounts payable, trade for fiscal 2025 was $110.00M, a 39.56% decline from fiscal 2024.
- Merck & Co., Inc. increase (decrease) in accounts payable, trade for fiscal 2024 was $182.00M.
- Merck & Co., Inc. increase (decrease) in accounts payable, trade for fiscal 2023 was -$380.00M.
- Merck & Co., Inc. increase (decrease) in accounts payable, trade for fiscal 2022 was -$289.00M, a 171.36% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month | Increase (Decrease) in Accounts Payable, Trade 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $110.00M 10-K · filed 2026-02-24 | ||||
| 2024-12-31 | $182.00M 10-K · filed 2026-02-24 | ||||
| 2023-12-31 | -$380.00M 10-K · filed 2026-02-24 | ||||
| 2022-12-31 | -$289.00M 10-K · filed 2025-02-25 | ||||
| 2021-12-31 | $405.00M 10-K · filed 2024-02-26 | ||||
| 2020-12-31 | $684.00M 10-K · filed 2023-02-24 | $724.00M 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $443.00M 10-K · filed 2022-02-25 | $399.00M 10-K · filed 2020-02-26 | |||
| 2018-12-31 | $230.00M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $254.00M 10-K · filed 2020-02-26 | ||||
| 2016-12-31 | $278.00M 10-K · filed 2019-02-27 | ||||
| 2015-12-31 | -$37.00M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $593.00M 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | $522.00M 10-K · filed 2016-02-26 | ||||
| 2012-12-31 | -$302.00M 10-K · filed 2015-02-27 | ||||
| 2011-12-31 | $182.00M 10-K · filed 2014-02-27 | ||||
| 2010-12-31 | $124.00M 10-K · filed 2013-02-28 | ||||
| 2009-12-31 | -$73.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | -$134.00M derived: sum of 2 quarters · filed 2012-02-28 | -$45.00M 10-K · filed 2012-02-28 | -$45.20M 10-K · filed 2010-03-01 | |
| 2009-09-30 | -$61.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-29 | $28.00M 10-Q · filed 2009-10-29 | |||
| 2009-06-30 | $89.00M 10-Q · filed 2009-07-24 | ||||
| 2008-12-31 | -$16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2010-03-01 | $21.00M derived: sum of 2 quarters · filed 2010-03-01 | $0.00 10-K · filed 2010-03-01 | ||
| 2008-09-30 | $37.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-29 | $16.00M 10-Q · filed 2009-10-29 | |||
| 2008-06-30 | -$21.00M 10-Q · filed 2009-07-24 | ||||
| 2007-12-31 | $117.70M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |